Advanced Glycation End Products: A Promising Prognostic Indicator in Breast Cancer Patients

Area of Science:

• Biochemistry
• Oncology
• Metabolic Disease

Background:

• Advanced glycation end products (AGEs) result from sugar reactions with proteins/lipids, accumulating in tissues and linked to diseases like cancer.
• Previous research indicates AGEs are associated with colon and pancreatic cancer progression.

Purpose of the Study:

• To investigate the association between AGEs and breast cancer.
• To determine if AGE levels differ between breast cancer patients and healthy controls.
• To explore the relationship between AGEs and clinical factors in breast cancer.

Main Methods:

• Quantified levels of glyoxal (GO) and methylglyoxal (MGO), key AGE precursors, in 60 stage 2-3 breast cancer patients and 21 controls.
• Collected blood samples pre- and post-surgery from patients and from controls.
• Utilized liquid chromatography for precise measurement of GO and MGO.

Main Results:

• Significantly elevated GO and MGO levels were observed in breast cancer patients compared to controls (p < 0.001).
• AGE precursor levels notably decreased in patients following surgical tumor removal.
• No significant correlations were found between AGE levels and breast cancer subtypes, age, menopausal status, or lymph node involvement.

Conclusions:

• The substantial reduction in AGE levels post-surgery suggests a correlation between tumor burden and AGE accumulation.
• While not definitively predictive, AGEs show potential as prognostic biomarkers for breast cancer.
• Monitoring AGE levels could prompt lifestyle modifications and potentially signal cancer recurrence or advancement.